← All candidates
Five insider buys in the last year — $54.0K in all.
48 filings on record.
DTILPRECISION BIOSCIENCES INC
NasdaqCM · Healthcare · $183.00M
$6.63
+0.30% · Sep 16
Five insider buys in the last year — $54.0K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 5 buys● 11 sells◆ 6 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what DTIL ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$183.00M
Float
25.5M
92% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
4.1
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Buehler Kevin
Bought $21.1K on Jun 25 — 5,076 sh @ $4.16, held direct, 18% of their stake.
1 of 1 position beat the S&P
Director
Germano Geno J
Bought $14.2K on Dec 16 — 3,000 sh @ $4.72, held direct, 13% of their stake.
2 of 2 positions beat the S&P
Director
Frankel Stanley
Bought $13.4K on Sep 26 — 2,700 sh @ $4.97, held direct, 16% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
43 more transactions on Pro →Context
Wall St
$29.60 avg target
+346.5% vs today · 5 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q1 '26−$0.75 act+$0.06
Q4 '25$1.01 act+$1.65
Q3 '25−$1.84 act+$0.37
Q2 '25−$2.13 act+$0.08
Coverage
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?Zacks · 07-08Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) ForecastsSimply Wall St. · 05-13Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue EstimatesZacks · 05-05Should You Buy Precision BioSciences (DTIL) After Golden Cross?Zacks · 04-14
The file stays open
48 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice